©2024 Stanford Medicine
Duloxetine for the Treatment of Dysthymia
Not Recruiting
Trial ID: NCT00185575
Purpose
The purpose of this study is to test the hypothesis that duloxetine (Cymbalta), in doses of
60 or 120 mg/day, is an effective and tolerable treatment for adult outpatients suffering
from dysthymia. Dysthymia is chronic, mild depression characterized by feeling sad or low
more days than not for more than 2 years.
Official Title
Duloxetine for the Treatment of Dysthymia
Stanford Investigator(s)
Elias Aboujaoude, MD, MA
Clinical Professor, Psychiatry and Behavioral Sciences
Eligibility
Inclusion Criteria::
- Sign an informed consent form
- 18 years of age or older
- Females not pregnant or breastfeeding or planning pregnancy and using an acceptable
form of contraception
- Meet DSM-IV criteria for dysthymia
- A screening IDS-C score of 17 or greater
- No history of serious or unstable medical disorder
- Not taking any significant concurrent medications
- Not currently receiving psychotherapy Exclusion Criteria:- Suffering from DSM-IV
defined
- delirium, dementia, amnestic, or other cognitive disorders
- mental disorders due to a general medical condition
- factitious or somatoform disorders
- mental retardation or developmental disabilities
- substance or alcohol abuse within the last 3 months
- depressive disorders with current suicidal risk
- psychotic disorders including delusional disorder, somatic type
- dissociative disorder
- personality disorders sufficiently severe to interfere with study participation
- History of DSM-IV defined bipolar I or II disorder
- History of non-response of dysthymia to adequate antidepressant medication
- History of major depression refractory to two adequate trials of antidepressants
Intervention(s):
drug: duloxetine
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Nona Gamel
6507255180